Robert Fletcher

Featured in: Favicon

wiley.com (+1) Favicon

nature.com Favicon

springer.com Favicon

bostonglobe.com Favicon

science.org Favicon

ahajournals.org Favicon

ace-eco.org Favicon

igbaffiliate.com Favicon

link.springer.com + 1 more

Articles

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials

Jan 23, 2025 | onlinelibrary.wiley.com | Safia Chatur |Muthiah Vaduganathan |Robert Fletcher |Vlado Perkovic

Introduction Patients with type 2 diabetes face heightened risk for the development of comorbid cardiovascular and kidney disease including heart failure (HF).1 The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been shown to reduce the risk of HF hospitalization or cardiovascular death among patients with type 2 diabetes at high cardiovascular and kidney risk across a broad range of patient subgroups in the CANVAS and CREDENCE trials, respectively.2, 3 Loop diuretics are...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →